Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

2025-10-16 11:55:45 ET

Intro

Alpha Tau Medical ( DRTS ) is pioneering the first and (as far as we are aware) only way of delivering alpha particle radiation locally to solid tumors. While the company is not currently well known, this represents a potentially significant breakthrough in oncology given that alpha radiation—which is significantly more effective at killing tumor cells than the beta, gamma, and X-ray radiation used in external beam radiation therapy (EBRT) and currently-approved radiopharmaceuticals—has historically been limited by its poor tissue penetrance and the risk of off-target damage.

The company’s device and procedure, Alpha DaRT, involves the insertion of “sources” (stainless steel or titanium needles) that are coated with Radium-224 directly into the tumor. As the Radium-224 decays, it recoils off of the source, emitting alpha particles and penetrating deeper into tissue as it continues down its six-leg decay chain. This allows for 500-1,000x enhanced tissue penetration of the alpha radiation (vs. its natural penetrance), which so far has enabled the beginnings of what appear to be best-in-class efficacy (and safety) in multiple solid tumor types ....

Read the full article on Seeking Alpha

For further details see: